Quick answer: The most evidence-supported longevity supplement stack for 2025 includes: NMN or NR for NAD+ precursor replenishment (NAD+ declines 50% by age 60), rapamycin (low-dose mTOR inhibition — the only intervention proven to extend lifespan in multiple mammalian species), metformin or berberine (AMPK activation with anti-glycation and senolytic properties), fisetin and quercetin (senolytics clearing p16+ senescent cells), urolithin A (mitophagy activation), and resveratrol or pterostilbene paired with NMN (SIRT1 activation) — each targeting distinct but interconnected longevity pathways.
The Biology of Aging: Nine Hallmarks and Their Targets
López-Otín et al. (2013, Cell; updated 2023 to include three additional hallmarks) identified nine primary hallmarks of aging — biological processes that accumulate with age and, when experimentally amplified, accelerate aging while, when suppressed, extend lifespan. A rationalized longevity stack targets multiple hallmarks simultaneously, exploiting the synergistic interactions between pathways:
The original nine hallmarks: genomic instability, telomere attrition, epigenetic alterations, loss of proteostasis, deregulated nutrient sensing, mitochondrial dysfunction, cellular senescence, stem cell exhaustion, and altered intercellular communication. The 2023 additions: disabled macroautophagy, chronic inflammation (inflammaging), and dysbiosis. A comprehensive longevity strategy requires interventions spanning all twelve.
NAD+ Precursors: NMN vs. NR
NAD+ (nicotinamide adenine dinucleotide) is the central metabolic cofactor for over 500 enzymatic reactions — electron carrier in oxidative phosphorylation, substrate for sirtuins (SIRT1–7), PARP enzymes (DNA repair), and CD38 (cyclic ADP-ribose signaling). NAD+ levels decline approximately 50% between age 20 and 60 in multiple human tissue types (Massudi et al., 2012; Camacho-Pereira et al., 2016) — a decline driven by increased PARP activity (responding to accumulated DNA damage), CD38 upregulation (NAD+-consuming ectoenzyme elevated in senescent and inflammatory cells), and decreased NAMPT (the rate-limiting enzyme in the NAD+ salvage pathway).
The two commercially available NAD+ precursors that have reached human clinical trial stage:
NMN (β-nicotinamide mononucleotide): Yoshino et al. (2021, Science, n=25 postmenopausal women, 10 weeks, 250 mg/day oral NMN) demonstrated significant increases in skeletal muscle NAD+ and insulin sensitivity, improved expression of insulin signaling genes, without side effects. NMN is directly converted to NAD+ via the Slc12a8 transporter (identified by Grozio et al., 2019, Nature Metabolism) — potentially more efficiently than NR in some tissues. Sublingual and liposomal NMN formulations are postulated to provide superior bioavailability over standard capsules. Standard clinical doses: 250–1,000 mg/day.
NR (nicotinamide riboside): Multiple human RCTs (Trammell et al., 2016, Nature Communications; Airhart et al., 2017, PLOS ONE) demonstrate NR increases whole-blood NAD+ dose-dependently (17–60% increases at 100–1,000 mg/day) with excellent safety profile. ChromaDex’s NIAGEN is the most studied NR formulation. 6-month NR supplementation trial (Martens et al., 2018, Nature Communications, n=24 older adults, 500 mg/day) showed blood NAD+ increases of 60% with reductions in circulating inflammatory markers, PBMC NAD+, and blood pressure. Standard clinical doses: 300–1,000 mg/day.
NMN vs. NR comparison: NMN has a phosphate group NR lacks — theoretically making it one step closer to NAD+ in the salvage pathway. Head-to-head comparison data in humans are limited. Both demonstrate blood NAD+ elevation; tissue-specific differences remain under investigation. The practical recommendation: either NMN (250–500 mg/day) or NR (300–600 mg/day) as a first-line NAD+ strategy; morning timing with food.
Rapamycin: The Most Evidence-Backed Longevity Drug
Rapamycin (sirolimus) is the only pharmacological intervention proven to extend maximum lifespan in multiple mammalian species under controlled conditions — including the landmark ITP (Interventional Testing Program) study (Harrison et al., 2009, Nature) showing 14% lifespan extension in mice when treatment began at age equivalent to 60 human years. Subsequent ITP studies confirmed the finding across multiple laboratories and mouse strains.
Mechanism: rapamycin inhibits mTORC1 (mechanistic Target Of Rapamycin Complex 1) by binding FKBP12, which then allosterically inhibits the mTOR kinase. mTORC1 is the master regulator of cellular growth and anabolic metabolism — sensing amino acids (via RAGULATOR/GATOR complexes), energy status (via AMPK), and growth factors (via PI3K/AKT). mTORC1 inhibition produces: enhanced autophagy (mTORC1 phosphorylates and inhibits ULK1, the autophagy initiator — rapamycin releases this brake), reduced protein synthesis (4EBP1 and S6K1 inhibition), reduced lipogenesis (SREBP1c inhibition), and indirect sirtuin activation (via mTORC1-SIRT6 crosstalk). Each of these effects addresses multiple aging hallmarks simultaneously.
Human clinical application: rapamycin is FDA-approved at 1–5 mg/day for organ transplant immunosuppression — doses that produce significant immunosuppression and metabolic side effects. The longevity dosing strategy (pioneered by Peter Attia, Matt Kaeberlein at University of Washington, and others) uses intermittent, low-dose rapamycin: 3–6 mg once weekly, exploiting the observation that mTORC1 inhibition during the off-week period produces durable autophagy/anti-aging effects while mTORC2 (critical for immune function and metabolic regulation) partially recovers between doses — potentially preserving immune competence. Mannick et al. (2014, Science Translational Medicine, rapalog RAD001, 6-week treatment in elderly adults) showed improved influenza vaccine response — evidence of immunostimulation rather than suppression at low intermittent dosing.
PEARL trial (Low-dose Rapamycin in Older Adults — NCT04514380) is the first RCT of rapamycin for longevity in healthy older adults; preliminary results are awaited. Contraindications at longevity doses: uncontrolled diabetes (rapamycin inhibits insulin signaling downstream of IRS-1, potentially worsening glucose metabolism at higher doses), active infection, concurrent CYP3A4 inhibitors (ketoconazole, grapefruit — dramatically increase rapamycin levels), hepatic impairment, and desire for pregnancy. Monitoring: rapamycin trough levels (target 3–8 ng/mL for transplant; longevity protocols often target 1–3 ng/mL intermittently), CBC, metabolic panel, lipids.
Metformin and Berberine: AMPK Activation
AMPK (AMP-activated protein kinase) is the cellular energy sensor activated by ATP depletion — the molecular mechanism underlying caloric restriction’s anti-aging effects. AMPK activation: suppresses mTORC1 (directly competing with rapamycin’s target), activates SIRT1 (via NAD+ restoration — AMPK activates NAMPT, the rate-limiting NAD+ synthesis enzyme), stimulates mitochondrial biogenesis (PGC-1α phosphorylation), promotes autophagy (phosphorylation of ULK1 at activating sites), and inhibits FASN (fatty acid synthase — reducing de novo lipogenesis). AMPK activation is therefore a longevity intervention converging on many of the same targets as rapamycin but through a complementary mechanism.
Metformin: FDA-approved for T2DM, metformin activates AMPK through Complex I inhibition (mild mitochondrial stress → ATP/AMP ratio increase → AMPK activation) and AMPK-independent mechanisms (PEN2/LYCAT pathway). The TAME trial (Targeting Aging with MEtformin, NCT03077438, n=3,000 older adults, 6-year follow-up) is the FDA-supported longevity RCT for metformin — testing whether metformin can delay the onset of age-associated conditions. MILES (Metformin in Longevity Study, Barzilai et al., 2016) provided pilot justification. Observational data: Bannister et al. (2014, Diabetes, Obesity and Metabolism, n=78,000) found T2DM patients on metformin outlived non-diabetic controls — a remarkable finding suggesting metformin’s benefits exceed glycemic control. Standard longevity dose: 500–1,500 mg/day (lower doses minimize GI side effects and B12 depletion — supplement B12 methylcobalamin with metformin).
Berberine: A plant alkaloid (Berberis, goldenseal, barberry) with demonstrated AMPK activation comparable to metformin in multiple cell and animal studies. Meta-analysis of 14 RCTs (Dong et al., 2012, Evidence-Based Complementary and Alternative Medicine) showed berberine reduced HbA1c by 0.90 percentage points — comparable to metformin. Additional mechanisms include: gut microbiome reshaping (enriches Akkermansia muciniphila and Faecalibacterium prausnitzii — butyrate-producing keystone species), PCSK9 inhibition (reducing LDL-C by an average of 25% in dyslipidemia trials), and advanced glycation end-product (AGE) inhibition. Standard dose: 500 mg three times daily with meals. Bioavailability is poor (<5%) — berberine phytosome (Berbevis) improves absorption 10-fold. Note: do not combine berberine with metformin without physician guidance — additive hypoglycemic effect in diabetics; in non-diabetics, the synergy may be beneficial but requires monitoring.
Senolytics: Clearing Senescent Cells
Cellular senescence — the stable cell cycle arrest of damaged cells accompanied by the SASP (Senescence-Associated Secretory Phenotype) — accumulates with aging and is now recognized as a direct driver of organ dysfunction, inflammation, and cancer. Senescent cells are present at low absolute numbers but their secretome (IL-6, IL-8, MMP-3, PAI-1, IGFBP-7) propagates senescence to neighboring cells and maintains chronic systemic low-grade inflammation (inflammaging). Baker et al. (2011, Nature) demonstrated that clearing p16INK4a-expressing senescent cells from BubR1 progeroid mice prevented multiple aging-associated phenotypes — a landmark proof-of-concept.
Dasatinib + Quercetin (D+Q): The first clinically tested senolytic combination. Dasatinib (ABL, Kit, PDGFR, and ephrin tyrosine kinase inhibitor — FDA-approved CML drug) selectively kills senescent adipocyte progenitors; quercetin clears senescent endothelial cells and macrophages. Kirkland et al. (2017, EBioMedicine, n=9 idiopathic pulmonary fibrosis) showed intermittent D+Q (dasatinib 100mg + quercetin 1,000mg, 3 days on/off, 3 weeks) reduced senescent cell markers in IPF lung tissue and improved physical function. Subsequent Mayo Clinic trials (Justice et al., 2019) in frail older adults confirmed senolytic biomarker reduction and functional improvement. The intermittent protocol (3 days per month) is key — continuous dosing is not more effective than intermittent for senolysis and increases side effect risk.
Fisetin: A flavonoid found in strawberries (160 μg/g), mangoes, and onions — with potent senolytic activity demonstrated in multiple cell lines and mouse aging models. Yousefzadeh et al. (2018, EBioMedicine) showed fisetin was the most potent senolytic among 10 tested flavonoids in human adipose tissue explants, and dramatically extended median and maximum lifespan in aged mice when started late (equivalent to age 75 human years). Human pilot data (Sharma et al., Mayo Clinic, NCT03675724) confirmed fisetin 20 mg/kg for 2 days reduced circulating senescent cell markers in older adults. Low bioavailability is a challenge — fat-soluble delivery (with high-fat meal or lipid formulation) substantially improves absorption. Typical protocol: fisetin 500–1,500 mg/day for 2 consecutive days monthly (intermittent senolytic dosing).
Quercetin alone: Beyond its role in D+Q, quercetin at higher doses (1,000–2,000 mg/day, 2 consecutive days monthly) demonstrates senolytic activity, particularly in endothelial and epithelial cells. Quercetin is also a SIRT1 activator, DAO enzyme activity supporter (relevant for MCAS), and NLRP3 inflammasome inhibitor — making it one of the highest-yield supplements per intervention in the functional medicine toolkit.
Urolithin A: Mitophagy Activation
Urolithin A is a gut microbiome metabolite produced from ellagic acid (found in pomegranates, walnuts, and berries) by specific gut bacteria — primarily Gordonibacter urolithinfaciens and Ellagibacter isourolithinifaciens. Urolithin A activates mitophagy (selective autophagy of damaged mitochondria) via PINK1/Parkin pathway activation and AMPK phosphorylation — directly addressing the mitochondrial dysfunction and loss of mitophagy that accumulates with aging.
Amazentis (now Nestlé Health Science) has conducted the most rigorous human trials with their proprietary Mitopure urolithin A formulation. Auwerx et al. (2022, Nature Aging, double-blind RCT, n=66 older adults, 4 months, 500 or 1,000 mg/day) demonstrated: 12–40% improvement in muscle endurance (six-minute walk test, hand grip), significant increases in mitochondrial gene expression (ATPB, NDUFB8, COX5B), and reductions in inflammatory markers (CRP, IL-6). Importantly, only 40% of individuals produce meaningful urolithin A from pomegranate/ellagic acid due to gut microbiome variation — making direct supplementation more reliable than dietary sourcing for most people. Standard dose: 500–1,000 mg/day Mitopure or equivalent standardized urolithin A.
Resveratrol and Pterostilbene: Sirtuin Activation
Resveratrol — the polyphenol from red grape skins and Japanese knotweed — activates SIRT1 (Howitz et al., 2003, Nature; confirmed by subsequent biophysical studies). SIRT1 deacetylates PGC-1α (driving mitochondrial biogenesis), p53 (modulating apoptosis/senescence balance), FOXO3 (upregulating antioxidant defense and stress resistance), and NF-κB (reducing inflammatory gene transcription). Resveratrol also directly inhibits mTORC1 at high concentrations and activates AMPK — positioning it as a caloric restriction mimetic.
Human clinical trials of resveratrol have been disappointing at standard doses (150–500 mg/day) — likely due to poor oral bioavailability (~1% of oral dose reaches systemic circulation as free resveratrol; 60–70% is absorbed but rapidly metabolized to inactive glucuronide and sulfate conjugates). Transresveratrol formulations with enhanced bioavailability (micronized resveratrol, resveratrol-cyclodextrin complexes, liposomal resveratrol) produce substantially higher plasma levels. The most promising clinical signals emerge at 1,000–2,000 mg/day: Tome-Carneiro et al. (2012, Molecular Nutrition & Food Research, n=75, resveratrol with grape extract vs. statin) showed comparable LDL-C reduction and superior anti-inflammatory and anti-platelet effects.
Pterostilbene — a dimethylated analog of resveratrol found in blueberries — has superior oral bioavailability (~80% vs. ~1%) and a longer half-life (105 min vs. 14 min for resveratrol). SIRT1 activation potency is comparable. Studies in rats show greater blood glucose reduction and cognitive protection than resveratrol at equivalent doses. The 2012 Pterostilbene and Grape Powder trial (Krikorian et al., Journal of Agricultural and Food Chemistry) showed cognitive benefit in older adults at 50 mg/day. Standard longevity dose: pterostilbene 50–250 mg/day, ideally combined with NMN/NR (synergistic SIRT1 activation via the SIRT1-NAD+ circuit).
Spermidine: Autophagy Induction
Spermidine is a polyamine — a naturally occurring molecule found at high concentrations in wheat germ, soybeans, aged cheese, mushrooms, legumes, and blood cells. Spermidine induces autophagy through a mechanism distinct from mTOR inhibition: it inhibits acetyltransferases EP300 and PCAF, producing specific autophagy-activating histone deacetylations. Eisenberg et al. (2009, Nature Cell Biology) identified spermidine as an autophagy inducer; subsequent work (2016, Nature Medicine) demonstrated spermidine supplementation extended lifespan in multiple model organisms (yeast, flies, worms, mice) and correlated inversely with all-cause mortality in 829 humans (Kiechl et al., 2018, American Journal of Clinical Nutrition — the highest quartile of dietary spermidine intake associated with 5-year reduction in mortality).
Human RCT data: Wirth et al. (2019, Cortex, n=85 older adults with subjective cognitive decline, 12 months, 0.9 mg/day spermidine from plant extract) showed significant improvement in memory performance — the first RCT-level evidence for spermidine’s cognitive benefits. Standard supplement dose: 1–6 mg/day spermidine (from wheat germ extract standardized to spermidine content). Dietary strategy: high-spermidine diet (wheat germ, mushrooms, soybeans, aged Cheddar/Emmental) provides 6–12 mg/day spermidine.
Alpha-Ketoglutarate (AKG): TET Enzyme Epigenetic Rejuvenation
Alpha-ketoglutarate (α-KG, also called 2-oxoglutarate) is a TCA cycle intermediate and obligate cofactor for TET methylcytosine dioxygenases (TET1/2/3) — the enzymes responsible for DNA demethylation (5mC → 5hmC → unmodified cytosine). TET enzymes are critical for maintaining proper epigenetic programming; their activity declines with aging as α-KG availability decreases relative to succinate (a TET inhibitor that accumulates in aging and cancer). Restoring α-KG:succinate ratio preserves TET activity, maintains epigenetic “youthfulness,” and has demonstrated lifespan extension in multiple model organisms.
Asadi Shahmirzadi et al. (2020, Cell Metabolism, aged mice, calcium α-KG oral supplementation) demonstrated 12% lifespan extension, 45% reduction in age-related inflammatory markers, and epigenetic age reversal by DNA methylation clock analysis. Human clinical trial: Demidenko et al. (2021, Aging, n=42 older adults, calcium alpha-ketoglutarate 1,000 mg/day, 7 months) showed GrimAge epigenetic clock reduction of 7 years on average — the largest epigenetic age reversal reported in any human supplement trial. Standard dose: 1,000–3,000 mg/day calcium alpha-ketoglutarate (Ca-AKG); take with meals (AKG is sour — it is the basis of Alpha-Ketoglutaric Acid or “Keto” acids used in nephrology as nitrogen-free amino acid analogs).
Timing, Synergies, and the Complete Stack Protocol
A practical longevity stack synthesizes the above interventions with attention to pharmacological interactions, timing synergies, and individual context:
Daily morning (with first meal): NMN 500 mg or NR 500 mg + pterostilbene 100 mg (NAD+-sirtuin axis); urolithin A (Mitopure) 500–1,000 mg (mitophagy); berberine phytosome 500 mg (AMPK/gut microbiome); Ca-AKG 1,000 mg (TET epigenetics); spermidine 3–6 mg (autophagy); omega-3 EPA+DHA 2–4g (anti-inflammaging, telomere protection).
Daily evening: Magnesium glycinate/threonate 300–400 mg (sleep/NMN recycling); vitamin D3 4,000–8,000 IU + K2 (MK-7) 180 μg (telomere/bone/cardiovascular); astaxanthin 12 mg (fat-soluble antioxidant; superior to lycopene/lutein for mitochondrial membrane protection); melatonin 0.3–1.0 mg (circadian entrainment + direct antioxidant at physiological doses — avoid 5–10mg supraphysiological doses that suppress endogenous production).
Weekly (intermittent senolytic protocol): 2 consecutive days/month: fisetin 1,000–1,500 mg/day (with high-fat meal for bioavailability) + quercetin 1,000–2,000 mg/day; or D+Q protocol (dasatinib 100mg + quercetin 1,000mg × 2 days — physician supervision required for dasatinib).
Weekly (mTOR inhibition — physician supervised): Rapamycin 3–6 mg once weekly. Confirm no active infection, CYP3A4 drug interactions, or contraindications. Monitor rapamycin trough, CBC, lipids, fasting glucose quarterly.
Critical stack interactions to be aware of: NMN/NR timing relative to intense exercise (post-workout NMN may blunt some exercise adaptation signals via AMPK-SIRT1 crosstalk — separate by 4–6 hours if competitive athletic performance is a priority); rapamycin + metformin (both mTOR and AMPK modification — consult physician; potential hypoglycemia risk in diabetics); high-dose quercetin + certain antibiotics (quercetin inhibits P-gp and CYP3A4 — can elevate levels of drugs cleared by these pathways).
Frequently Asked Questions About Longevity Supplements
Is there a single best longevity supplement?
No single supplement addresses all 12 hallmarks of aging. The most mechanistically comprehensive single agents are rapamycin (mTOR inhibition with downstream autophagy, protein synthesis, senescence, and immune modulation effects), NMN/NR (NAD+ restoration affecting sirtuins, PARPs, and mitochondrial function), and Ca-AKG (TET epigenetic restoration with GrimAge clock reduction). Rapamycin has the strongest longevity evidence from animal trials; Ca-AKG has the most impressive human epigenetic clock data; NMN/NR have the most robust human safety and metabolic data. A stacked protocol outperforms any single agent.
At what age should longevity supplementation begin?
The hallmarks of aging begin accumulating in the late twenties — detectable NAD+ decline starts around age 30; epigenetic drift (measurable by DNA methylation clocks) begins in the early thirties; senescent cell burden begins meaningfully rising in the late thirties. Early intervention prevents accumulation rather than reversing existing damage — mechanistically arguing for starting in the 30s–40s. Practical prioritization: NAD+ support and lifestyle optimization (Zone 2 exercise, time-restricted eating, sleep) first; add senolytic and mTOR interventions in the 40s–50s under physician guidance. Rapamycin and senolytics at younger ages are less studied and require more conservative risk-benefit assessment.
Can longevity supplements interact with medications?
Yes — important interactions include: rapamycin with immunosuppressants, CYP3A4 inhibitors, and antifungals (dramatic level elevation); berberine with metformin (additive hypoglycemia risk); quercetin with cyclosporine, statins, and certain antibiotics (P-gp/CYP3A4 inhibition); NMN/NR with PARP inhibitors (direct competition for NAD+); resveratrol with warfarin (CYP2C9 inhibition → elevated INR). Review all supplements and medications with a physician before starting any longevity protocol — a complete pharmaceutical and supplement interaction review is standard at our functional medicine consultations.
How is longevity supplementation monitored?
A functional medicine longevity monitoring panel includes: epigenetic biological age (Horvath clock, GrimAge, DunedinPACE — available from TruDiagnostic, Elysium Index, or Zymo Research); NAD+ levels (Jinfiniti intracellular NAD+ testing); telomere length (SpectraCell TelomerePlus, LifeLength — for baseline and longitudinal tracking); advanced metabolic panel (fasting insulin, HOMA-IR, ApoB, LDL-P, LP(a), hsCRP, homocysteine); inflammatory biomarkers (IL-6, TNF-α, GDF-15 — the latter is an emerging longevity biomarker that predicts mortality independently of standard risk factors); comprehensive hormone panel; and annual DEXA for body composition. Reassess every 6–12 months to guide protocol optimization.
Designing an individualized longevity protocol requires understanding your current biological age versus chronological age, identifying your dominant hallmarks of aging, and sequencing interventions based on your specific biomarker profile and goals. Our functional medicine team at The Private Practice provides comprehensive longevity assessment and evidence-based supplementation design. Call us at (810) 206-1402 to begin your longevity optimization journey.
Related Articles
- Zone 2 Training & Longevity: The Evidence
- NAD+, NMN & NR Supplements: The Science
- Optimal Vitamin D Levels: What the Research Shows